Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLRNYSE:CANFNASDAQ:CMMBNASDAQ:EDSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.00+2.1%$0.98$0.61▼$7.45$15.08M-0.151.13 million shs294,547 shsCANFCan-Fite BioPharma$1.04+0.5%$1.09$0.98▼$4.69$3.66M1.12239,475 shs107,218 shsCMMBChemomab Therapeutics$1.17-2.0%$1.28$0.87▼$2.55$22.07M0.48218,856 shs69,875 shsEDSAEdesa Biotech$2.05+5.0%$2.08$1.55▼$5.59$14.39M0.41491,989 shs2,880 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%+7.52%+18.33%+6.37%-84.34%CANFCan-Fite BioPharma0.00%-1.90%-3.72%-30.07%-59.88%CMMBChemomab Therapeutics0.00%-2.50%-10.00%+7.34%+28.22%EDSAEdesa Biotech0.00%+4.59%+2.50%-15.98%-52.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.7971 of 5 stars0.04.00.00.01.40.01.3CANFCan-Fite BioPharma2.6324 of 5 stars3.75.00.00.00.00.01.3CMMBChemomab Therapeutics2.8226 of 5 stars3.53.00.00.02.71.70.6EDSAEdesa Biotech1.7288 of 5 stars2.03.00.00.03.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 0.00N/AN/AN/ACANFCan-Fite BioPharma 3.33Buy$14.001,252.66% UpsideCMMBChemomab Therapeutics 3.00Buy$8.50626.50% UpsideEDSAEdesa Biotech 4.00Strong Buy$5.00143.90% UpsideCurrent Analyst Ratings BreakdownLatest CANF, ALLR, CMMB, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.005/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.004/15/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/ACANFCan-Fite BioPharma$674K5.44N/AN/A$1.76 per share0.59CMMBChemomab TherapeuticsN/AN/AN/AN/A$0.72 per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)CANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACMMBChemomab Therapeutics-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)Latest CANF, ALLR, CMMB, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/A5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ACANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.662.66CANFCan-Fite BioPharmaN/A2.93N/ACMMBChemomab TherapeuticsN/A5.335.33EDSAEdesa BiotechN/A15.7215.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%CANFCan-Fite BioPharma21.00%CMMBChemomab Therapeutics46.05%EDSAEdesa Biotech5.50%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.01%CANFCan-Fite BioPharma0.80%CMMBChemomab Therapeutics11.91%EDSAEdesa Biotech22.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.08 million15.08 millionNot OptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCMMBChemomab Therapeutics2018.86 million16.61 millionNot OptionableEDSAEdesa Biotech207.02 million5.44 millionNot OptionableCANF, ALLR, CMMB, and EDSA HeadlinesRecent News About These CompaniesEdesa Biotech (NASDAQ:EDSA) Earns "Buy" Rating from HC WainwrightJune 28 at 3:02 AM | americanbankingnews.comEDSA: Advancing EB06 for the Treatment of Vitiligo…May 20, 2025 | msn.comPositive Signs As Multiple Insiders Buy Edesa Biotech StockMay 18, 2025 | finance.yahoo.comEdesa Biotech, Inc.: Edesa Biotech Reports Fiscal 2nd Quarter 2025 ResultsMay 16, 2025 | finanznachrichten.deEdesa Biotech Reports Fiscal 2nd Quarter 2025 ResultsMay 14, 2025 | globenewswire.comEdesa Biotech to Participate in Bloom Burton Healthcare Investor ConferenceApril 28, 2025 | globenewswire.comEdesa Biotech Appoints Weiler as CFO, Succeeding LemieuxApril 5, 2025 | marketwatch.comEdesa Biotech says Peter Weiler to succeed Stephen Lemieux as CFOApril 5, 2025 | markets.businessinsider.comEdesa Biotech Announces Chief Financial Officer TransitionApril 4, 2025 | globenewswire.comEdesa Biotech files to sell 7.81M common shares for holdersMarch 4, 2025 | markets.businessinsider.comEDSA: Raises $15 Million to Advance EB06…March 3, 2025 | finance.yahoo.comEdesa Biotech Reports Fiscal 1st Quarter 2025 ResultsFebruary 14, 2025 | financialpost.comFEdesa Biotech Reports Fiscal 1st Quarter 2025 ResultsFebruary 14, 2025 | financialpost.comFEdesa Biotech Reports Fiscal 1st Quarter 2025 ResultsFebruary 14, 2025 | globenewswire.comEdesa Biotech secures $15 million for clinical programFebruary 13, 2025 | msn.comEdesa Biotech announces $15M private placement priced at-the-marketFebruary 13, 2025 | markets.businessinsider.comEdesa Biotech, Inc. Announces $15 Million Private Placement to Advance CXCL10 Antibody ProgramFebruary 13, 2025 | quiverquant.comQEdesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesFebruary 13, 2025 | globenewswire.comEDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo…January 22, 2025 | finance.yahoo.comEdesa Biotech And 2 Other Promising US Penny Stocks For Your RadarDecember 18, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANF, ALLR, CMMB, and EDSA Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.00 +0.02 (+2.12%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.01 +0.02 (+1.51%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Can-Fite BioPharma NYSE:CANF$1.03 +0.01 (+0.49%) Closing price 06/27/2025 03:53 PM EasternExtended Trading$1.95 +0.92 (+88.41%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Chemomab Therapeutics NASDAQ:CMMB$1.17 -0.02 (-1.98%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$1.80 +0.63 (+53.85%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Edesa Biotech NASDAQ:EDSA$2.05 +0.10 (+5.03%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.94 -0.12 (-5.61%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
